Comparison of Markov model and discrete-event simulation techniques for HIV

PharmacoEconomics

Volumn 27, Issue 2, 2009, Pages 159-165

  Simpson, Kit N ^a,d   Strassburger, Alvin ^a   Jones, Walter J ^a   Dietz, Birgitta ^b   Rajagopalan, Rukmini ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

^c ABBOTT LABORATORIES   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SIMULATION; VIRUS LOAD;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; MODELS, STATISTICAL; PYRIMIDINONES; RITONAVIR;

EID: 61749095518     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927020-00006     Document Type: Article

References (30)

1. Weinstein M, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 6 (9): 9-17
2. Stahl JE. Modeling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmaceconomics 2008; 26 (2): 131-48
3. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23 (4): 323-32
4. Patten SB. An animated depiction of major depression epidemiology. BMC Psychiatry 2007; 7: 23
5. Matta ME, Patterson SS. Evaluating multiple performance measures across several dimensions at a multi-facility outpatient center. Health Care Manag Sci 2007; 10 (2): 173-94
6. FDA Center for Drug Evaluation and Research. Application 21-567 statistical review(s) 2002 [online]. Available from URL: http://www.fda.gov/ cder/foi/nda/2003/21-567-Reyataz-Statr.pdf [Accessed 2006 Nov 7]
7. Hicks C. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4-year follow-up study. AIDS 2004; 18: 775-9
8. Johnson M, Grinsztejn B, Rodrigues C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19 (7): 685-94
9. Johnson M, Grinsztejn B, Rodrigues C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virological failures. AIDS 2006; 20 (5): 711-8
10. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir in antiretroviral-naive patients: 48-week results [poster #570]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA) [online]. Available from URL: http:// www.retroconference.org/ 2004/cd/PDFs/570.pdf [Accessed 2007 Oct 22]
11. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir vs. nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346 (26): 2039-46
12. Simpson KN, Voit EO, Goodman R, et al. Estimating the social and economic benefits of pharmaceutical innovations: modeling clinical trial results in HIV-disease. Res Hum Cap Dev 2001; 14: 175-98
13. Simpson KN, Luo MP, Chumney ECG, et al. Cost effectiveness of lopinavir/ritonavir versus nelfinavir as the firstline highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5 (5): 294-304
14. Simpson KN, Luo M, Chumney ECG, et al. Cost-effectiveness of lopinavir/ritonavir compared to atazanavir in antiretroviral-naïve patients: modeling the combined effects of HIV and heart disease. Clin Drug Invest 2007; 27 (1): 67-74
15. Simpson KN, Jones WJ, Rajagopalan R, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Invest 2007; 27 (7): 443-52
16. Murphy R, daSilva B, McMillan F, et al. Seven year follow-up of a lopinavir/ritonavir-based regimen in antiretroviral naïve subjects [poster PE7.9-7]. 10th European AIDS Conference; 2005 Nov 17-20; Dublin
17. Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043-53
18. Weinstein MC, Coxon PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health 1907; 77 (11): 1417-26
19. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277 (7): 535-42
20. Simpson KN. Design and assessment of cost effectiveness studies in AIDS populations. JAIDS 1995; 10 Suppl. 4: S28-32
21. Schulman KA, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114: 798-802
22. Simpson K, Andersson F, Shakespeare A, et al. Cost effectiveness of antiviral treatment with zalcitabine in combination with zidovudine for AIDS patients with CD4 counts 300 per mm3 in five European countries. Pharmacoeconomics 1994; 6 (6): 553-62
23. Chancellor J, Hill A, Simpson K, et al. Cost effectiveness of 3TC and ZDV in patients with HIV-Disease. Pharmacoeconomics 1997; 12 (1): 1-13
24. Biddle AK, Simpson KN. Modeling the cost effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kingdom. J Med Econ 1999; 2: 85-105
25. Schackman BR, Goldie SJ, Weinstein MC, et al. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health 2001; 91 (9): 1456-63
26. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med 2005; 352 (6): 586-95
27. Mauskopf J, Lacey L, Kempel A, et al. The cost effectiveness of treatment with lamivudine and zidovudine compared to zidovudine alone: a comparison of Markov model and trial data estimates. Am J Managed Care 1998; 4 (7): 1004-12
28. Phillips Z, Bojke L, Schulper M, et al. Good practice guidelines for decision-analytic modeling in health technology assessment. Pharmacoeconomics 2006; 24 (4): 355-71
29. Rockwell Automation. Arena®. Warrendale (PA) [online]. Available from URL: http://www.arenasimulation.com/ [Accessed 2008 Nov 21]
30. Garrison LP. The ISPOR good practice modeling principles: a sensible approach. Be transparent be reasonable. Value Health 2003; 6 (1): 6-8